TY - JOUR

T1 - Two nights of home polysomnography in healthy 7-14-year-old children – Feasibility and intraindividual variability

AU - Pedersen, Malthe Jessen

AU - Leonthin, Helle

AU - Mahler, Birgitte

AU - Rittig, Søren

AU - Jennum, Poul Jørgen

AU - Kamperis, Konstantinos

N1 - Publisher Copyright: © 2022 The Authors

PY - 2023

Y1 - 2023

N2 - Objective: Attended polysomnography (PSG) is the gold standard for childhood sleep evaluation. There is, however, only limited information regarding repeated ambulatory PSG in children. We aimed to test whether in hospital attached level 2 home PSG is feasible and reproducible in healthy children. Methods: We recruited healthy children aged 7-14 years to undergo two nights of full level 2 PSG. The PSG equipment was attached at the hospital on the day of the sleep test and all recordings were performed at home. Subjective sleep quality, nocturnal urine production, sleep time and number of awakenings were documented for a week in connection to the first PSG night. Results: Thirty-three children were recruited of whom 32 children (aged 11 ± 2.1 years) underwent two nights of PSG. All 64 PSGs were technically adequate for sleep evaluation. We found mean sleep efficiency of 94% and mean total sleep time of 8.4 h. Sleep stages distribution with 5.9% N1, 46.8% N2, 24.3% N3 and 22.8% REM sleep. We found poorer subjective sleep quality, more self-reported awakenings, and shorter total sleep time on nights with PSG compared to nights without PSG with no differences between PSG study nights. No differences in nocturnal urine production were found between nights with and without PSG. The comparison of PSG variables between the two PSG nights revealed no first night effect. Conclusions: Type 2 PSG recording is feasible for sleep evaluation in children 7–14 years of age producing good data quality. We found no first night effect on PSG variables. www.clinicaltrials.gov Registration number: NCT03477812.

AB - Objective: Attended polysomnography (PSG) is the gold standard for childhood sleep evaluation. There is, however, only limited information regarding repeated ambulatory PSG in children. We aimed to test whether in hospital attached level 2 home PSG is feasible and reproducible in healthy children. Methods: We recruited healthy children aged 7-14 years to undergo two nights of full level 2 PSG. The PSG equipment was attached at the hospital on the day of the sleep test and all recordings were performed at home. Subjective sleep quality, nocturnal urine production, sleep time and number of awakenings were documented for a week in connection to the first PSG night. Results: Thirty-three children were recruited of whom 32 children (aged 11 ± 2.1 years) underwent two nights of PSG. All 64 PSGs were technically adequate for sleep evaluation. We found mean sleep efficiency of 94% and mean total sleep time of 8.4 h. Sleep stages distribution with 5.9% N1, 46.8% N2, 24.3% N3 and 22.8% REM sleep. We found poorer subjective sleep quality, more self-reported awakenings, and shorter total sleep time on nights with PSG compared to nights without PSG with no differences between PSG study nights. No differences in nocturnal urine production were found between nights with and without PSG. The comparison of PSG variables between the two PSG nights revealed no first night effect. Conclusions: Type 2 PSG recording is feasible for sleep evaluation in children 7–14 years of age producing good data quality. We found no first night effect on PSG variables. www.clinicaltrials.gov Registration number: NCT03477812.

KW - Ambulatory

KW - Children

KW - Polysomnography

KW - Sleep

U2 - 10.1016/j.sleep.2022.10.027

DO - 10.1016/j.sleep.2022.10.027

M3 - Journal article

C2 - 36368073

AN - SCOPUS:85141740408

VL - 101

SP - 87

EP - 92

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

ER -